Zimmerman and colleagues examined how many depressed patients who scored in the remission range on the 17-item Hamilton Depression Rating Scale (HDRS) did not consider themselves to be in remission ...
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
The FDA lifted its clinical hold on GH Research's GH001 after Phase 2b data showed rapid, durable benefits in ...
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison ...
Despite the disappointing primary results, Biohaven noted some positive trends in specific subgroups, particularly among patients with more severe depression at screening and baseline. The company ...
Biohaven’s phase 2 proof-of-concept study with BHV-7000 in major depressive disorder fails to meet its primary endpoint: New Haven, Connecticut Monday, December 29, 2025, 13:00 ...
MedPage Today on MSN
Fish Oil Flopped for Kids With Major Depressive Disorder
Adding a daily fish oil supplement to psychotherapy showed no significant benefit over placebo for kids and teens with ...
Verywell Health on MSN
Cymbalta vs. Lexapro for depression: Which is better?
Medically reviewed by Mary Choy, PharmD Key Takeaways Cymbalta and Lexapro are both used to treat depression and anxiety disorders, but they are different drug classes.Cymbalta is also approved to ...
Dealing with mental health conditions like depression can be challenging. Some people struggle to find the right treatment or combination of treatments for their condition. In major depression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback